Caroline H. Siegel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Caroline H. Siegel has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Lisa R. Sammaritano
Division of Rheumatology, Hospital for Special Surgery, and the Department of Medicine, Weill Cornell Medicine, New York, New York
5 shared publications- Deanna Jannat-Khah
Hospital for Special Surgery, New York, NY, USA Weill Cornell Medicine, New York NY USA
2 shared publications - Iris Navarro-Millán
Hospital for Special Surgery and Weill Cornell Medicine New York New York
2 shared publications - Lisa A. Mandl
Division of Rheumatology, Hospital for Special Surgery, and Weill Cornell Medicine, New York, New York (L.A.M.).
2 shared publications - Lisa R. Sammaritano
Hospital for Special Surgery, Weill Cornell Medicine New York New York
2 shared publications Medha Barbhaiya
Department of Medicine, Division of Rheumatology, Hospital for Special Surgery-Weill Cornell Medicine, New York, NY, USA
2 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 13 (5) , 1203-1221
Fertility and Birth Outcomes in Rheumatoid Arthritis: A Narrative Review
- 20 August 2026
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 13 (5) , 1203-1221
Open AccessFertility and Birth Outcomes in Rheumatoid Arthritis: A Narrative Review
- 19 February 2026
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
Biologic Disease-Modifying Antirheumatic Drug Use During Pregnancy and Lactation
Autoimmune rheumatic diseases (ARDs) are chronic diseases characterized by periods of flare and remission. Autoimmune rheumatic diseases are often diagnosed in reproductive-aged women, and treatment decisions must factor in pregnancy potential and intent. Well-controlled maternal disease in the prepregnancy period and during pregnancy portends improved maternal and fetal outcomes. Although conventional immunosuppressant and agents remain a mainstay of treatment, use of biologic disease-modifying antirheumatic drugs (bDMARDs), either alone or in combination with conventional agents, is increasingly common. Multiple professional societies have published formal evidence-based guidelines with recommendations for ARD treatment during pregnancy and lactation. This review focuses on the use of bDMARDs during pregnancy and lactation and the safety of infant vaccination after in utero exposure; we synthesize current evidence, summarize guideline recommendations, and present practical management strategies. In general, guidelines support the use of bDMARDs during pregnancy and in the postpartum period to maintain disease control. Among biologic classes, tumor necrosis factor inhibitors have the most robust evidence establishing safety for use during pregnancy and lactation. Safety data for newer agents with differing targets or mechanisms of action are often lacking. Teratogenicity is unlikely; large-molecule monoclonal antibodies do not cross the placenta until after organogenesis. The main concerns with treatment during pregnancy are potential effects on the neonatal immune system and other unknown consequences of in utero exposure. Risks of treatment are often outweighed by benefits, especially for maternal disease refractory to other pregnancy-compatible options. Additional research is needed to inform individualized counseling and shared decision making.
- 19 February 2026
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
Biologic Disease-Modifying Antirheumatic Drug Use During Pregnancy and Lactation
Autoimmune rheumatic diseases (ARDs) are chronic diseases characterized by periods of flare and remission. Autoimmune rheumatic diseases are often diagnosed in reproductive-aged women, and treatment decisions must factor in pregnancy potential and intent. Well-controlled maternal disease in the prepregnancy period and during pregnancy portends improved maternal and fetal outcomes. Although conventional immunosuppressant and agents remain a mainstay of treatment, use of biologic disease-modifying antirheumatic drugs (bDMARDs), either alone or in combination with conventional agents, is increasingly common. Multiple professional societies have published formal evidence-based guidelines with recommendations for ARD treatment during pregnancy and lactation. This review focuses on the use of bDMARDs during pregnancy and lactation and the safety of infant vaccination after in utero exposure; we synthesize current evidence, summarize guideline recommendations, and present practical management strategies. In general, guidelines support the use of bDMARDs during pregnancy and in the postpartum period to maintain disease control. Among biologic classes, tumor necrosis factor inhibitors have the most robust evidence establishing safety for use during pregnancy and lactation. Safety data for newer agents with differing targets or mechanisms of action are often lacking. Teratogenicity is unlikely; large-molecule monoclonal antibodies do not cross the placenta until after organogenesis. The main concerns with treatment during pregnancy are potential effects on the neonatal immune system and other unknown consequences of in utero exposure. Risks of treatment are often outweighed by benefits, especially for maternal disease refractory to other pregnancy-compatible options. Additional research is needed to inform individualized counseling and shared decision making.
- Open Access
- 23 January 2025
- Published by Wiley in ACR Open Rheumatology
- Vol. 7 (1) , e11775
Increasing Contraception Documentation in an Academic Rheumatology Clinic: A Quality Improvement Approach
Objective: This quality improvement initiative aimed to increase the rate of provider screening and documentation of contraception use for reproductive‐aged women seen in an academic rheumatology fellows’ clinic to >50% by 24 weeks, with sustained improvement at one year.Methods: With a multidisciplinary team, we devised and implemented six interventional cycles over 24 weeks informed by key stakeholder survey responses. The primary outcome measure was the percentage of eligible visits with contraception information documented in the structured electronic health record field. The smoking status documentation rate was tracked as a balancing measure, and the percentage of contraception documenters who were non–medical doctor (MD) clinical staff, the target group for the intervention, was tracked as a process measure. Outcome, process, and balancing measures were assessed every two weeks over one year.Results: Over 24 weeks, the rate of contraception documentation increased from 11% to 54% (median 30%), and the median smoking status documentation rate was 88% (68%–97% range); the median rate of non‐MD clinical staff documenters was 92% (70%–100% range). Interventions included an introductory educational session with documentation instruction and scripts to guide screening, email reminders from nursing leadership, and interim educational sessions. At one year, the contraception documentation rate was sustained at 50%.Conclusion: A multicycle educational intervention led to an increase in the contraception documentation rate from 11% to 54% for reproductive‐aged women seen in an academic rheumatology fellows’ clinic over 24 weeks, with sustained improvement at one year. Future interventions will focus on increasing contraception counseling and referrals for patients in rheumatology clinics who were high risk.
- 23 January 2025
- Published by Wiley in ACR Open Rheumatology
- Vol. 7 (1) , e11775
Open AccessIncreasing Contraception Documentation in an Academic Rheumatology Clinic: A Quality Improvement Approach
Objective: This quality improvement initiative aimed to increase the rate of provider screening and documentation of contraception use for reproductive‐aged women seen in an academic rheumatology fellows’ clinic to >50% by 24 weeks, with sustained improvement at one year.Methods: With a multidisciplinary team, we devised and implemented six interventional cycles over 24 weeks informed by key stakeholder survey responses. The primary outcome measure was the percentage of eligible visits with contraception information documented in the structured electronic health record field. The smoking status documentation rate was tracked as a balancing measure, and the percentage of contraception documenters who were non–medical doctor (MD) clinical staff, the target group for the intervention, was tracked as a process measure. Outcome, process, and balancing measures were assessed every two weeks over one year.Results: Over 24 weeks, the rate of contraception documentation increased from 11% to 54% (median 30%), and the median smoking status documentation rate was 88% (68%–97% range); the median rate of non‐MD clinical staff documenters was 92% (70%–100% range). Interventions included an introductory educational session with documentation instruction and scripts to guide screening, email reminders from nursing leadership, and interim educational sessions. At one year, the contraception documentation rate was sustained at 50%.Conclusion: A multicycle educational intervention led to an increase in the contraception documentation rate from 11% to 54% for reproductive‐aged women seen in an academic rheumatology fellows’ clinic over 24 weeks, with sustained improvement at one year. Future interventions will focus on increasing contraception counseling and referrals for patients in rheumatology clinics who were high risk.
- 1 October 2024
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 30 (7S) , S25-S33
Safety of Medications Used to Treat Autoimmune Rheumatic Diseases During Pregnancy and Lactation
Autoimmune rheumatic diseases (ARDs) often affect women during their reproductive years, and early studies of pregnancy in these patients reported high rates of adverse outcomes. Continuation or initiation of safe and effective medications in the preconception period is beneficial for maintaining or achieving disease quiescence throughout pregnancy thereby improving both maternal and pregnancy outcomes. The European Alliance of Associations for Rheumatology, the American College of Rheumatology, and the British Society for Rheumatology have published recommendations and guidelines regarding management of ARDs during pregnancy. The American College of Obstetricians and Gynecologists and the American Gastroenterological Association have also provided guidance statements with relevant recommendations. This review provides an overview of available recommendations for medication use in ARD pregnancy, with discussion of safety considerations for maternal and fetal well-being. Medications considered compatible with pregnancy include hydroxychloroquine, sulfasalazine, azathioprine, cyclosporine, tacrolimus, and TNF inhibitors. Methotrexate, mycophenolate, leflunomide, and cyclophosphamide should be avoided before and during pregnancy. Other medications, most of them newer, are largely discouraged for use in pregnancy due to inadequate data or concerns for neonatal immunosuppression, including non-TNF biologics and small molecule therapies. Further investigation is needed regarding effects of non-TNF biologics, biosimilars, and small molecules in pregnancy. Important efforts for the future will include improved methodologies to gather critical safety data, with consideration of inclusion of pregnant women in clinical trials, a complex and controversial issue. Long-term information on outcomes in offspring of treated women is lacking for many of these medications.
- 1 October 2024
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 30 (7S) , S25-S33
Safety of Medications Used to Treat Autoimmune Rheumatic Diseases During Pregnancy and Lactation
Autoimmune rheumatic diseases (ARDs) often affect women during their reproductive years, and early studies of pregnancy in these patients reported high rates of adverse outcomes. Continuation or initiation of safe and effective medications in the preconception period is beneficial for maintaining or achieving disease quiescence throughout pregnancy thereby improving both maternal and pregnancy outcomes. The European Alliance of Associations for Rheumatology, the American College of Rheumatology, and the British Society for Rheumatology have published recommendations and guidelines regarding management of ARDs during pregnancy. The American College of Obstetricians and Gynecologists and the American Gastroenterological Association have also provided guidance statements with relevant recommendations. This review provides an overview of available recommendations for medication use in ARD pregnancy, with discussion of safety considerations for maternal and fetal well-being. Medications considered compatible with pregnancy include hydroxychloroquine, sulfasalazine, azathioprine, cyclosporine, tacrolimus, and TNF inhibitors. Methotrexate, mycophenolate, leflunomide, and cyclophosphamide should be avoided before and during pregnancy. Other medications, most of them newer, are largely discouraged for use in pregnancy due to inadequate data or concerns for neonatal immunosuppression, including non-TNF biologics and small molecule therapies. Further investigation is needed regarding effects of non-TNF biologics, biosimilars, and small molecules in pregnancy. Important efforts for the future will include improved methodologies to gather critical safety data, with consideration of inclusion of pregnant women in clinical trials, a complex and controversial issue. Long-term information on outcomes in offspring of treated women is lacking for many of these medications.
- 8 August 2024
- Published by American Medical Association (AMA) in JAMA
- Vol. 332 (9)
Review of Systemic Lupus Erythematous—Reply
In Reply The Letter to the Editor from Dr Watkins and colleagues about our Review on SLE raises the important topic of congenital heart block risk for the
- 8 August 2024
- Published by American Medical Association (AMA) in JAMA
- Vol. 332 (9)
Review of Systemic Lupus Erythematous—Reply
In Reply The Letter to the Editor from Dr Watkins and colleagues about our Review on SLE raises the important topic of congenital heart block risk for the
- Open Access
- 1 January 2023
- Published by Touch Medical Media, Ltd. in touchREVIEWS in RMD
- Vol. 2 (1)
Challenges in Family Planning and Pregnancy for Women with Rheumatic Diseases
Systemic rheumatic diseases (RDs) often affect women in their reproductive years and may complicate family planning and pregnancy. For women with RD who are not pursuing pregnancy, especially those at the highest risk of maternal morbidity or on teratogenic medications, effective contraception is important. For women with active systemic lupus erythematosus (SLE) and/or antiphospholipid antibodies, oestrogen-containing contraceptive methods are generally not recommended. Emergency contraception and induced abortion are safe for women with RD and should be discussed when clinically appropriate. Women with RD commonly have questions and concerns about the impact of their disease on fertility and conception. RD-associated factors may contribute to difficulties in conceiving and decreased family size. Assisted reproductive technology (ART) is often a safe option for women with RD. However, precautions and specific treatment modifications may be needed, particularly in women with SLE and/or antiphospholipid antibody positivity. SLE and antiphospholipid syndrome (APS) are the RDs associated with the greatest risk of maternal and foetal pregnancy complications. Regardless of the specific RD, having an active disease is a significant risk factor for poor pregnancy outcomes. With appropriate preconception planning and multidisciplinary management during and after pregnancy, most women with RD can have successful pregnancies.
- 1 January 2023
- Published by Touch Medical Media, Ltd. in touchREVIEWS in RMD
- Vol. 2 (1)
Open AccessChallenges in Family Planning and Pregnancy for Women with Rheumatic Diseases
Systemic rheumatic diseases (RDs) often affect women in their reproductive years and may complicate family planning and pregnancy. For women with RD who are not pursuing pregnancy, especially those at the highest risk of maternal morbidity or on teratogenic medications, effective contraception is important. For women with active systemic lupus erythematosus (SLE) and/or antiphospholipid antibodies, oestrogen-containing contraceptive methods are generally not recommended. Emergency contraception and induced abortion are safe for women with RD and should be discussed when clinically appropriate. Women with RD commonly have questions and concerns about the impact of their disease on fertility and conception. RD-associated factors may contribute to difficulties in conceiving and decreased family size. Assisted reproductive technology (ART) is often a safe option for women with RD. However, precautions and specific treatment modifications may be needed, particularly in women with SLE and/or antiphospholipid antibody positivity. SLE and antiphospholipid syndrome (APS) are the RDs associated with the greatest risk of maternal and foetal pregnancy complications. Regardless of the specific RD, having an active disease is a significant risk factor for poor pregnancy outcomes. With appropriate preconception planning and multidisciplinary management during and after pregnancy, most women with RD can have successful pregnancies.
- Open Access
- 13 December 2022
- Published by BMJ in Lupus Science & Medicine
- Vol. 9 (1) , e000840
Infertility in systemic lupus erythematosus: what rheumatologists need to know in a new age of assisted reproductive technology
Fertility is often a concern for women with SLE. In addition to known indirect factors that influence the ability of a woman with SLE to become pregnant, such as cytotoxic agents, other medications, advanced age and psychosocial effects of the disease, direct disease-related factors are believed to influence fertility. These include diminished ovarian reserve, menstrual irregularities (a function of disease activity) and the presence of antiphospholipid antibodies. The question of whether SLE intrinsically affects fertility, however, remains unanswered. In this review, we address known factors affecting fertility, assess current data regarding a direct impact of SLE on fertility and evaluate potential disease-related risk factors. We focus primarily on studies measuring anti-Müllerian hormone and antral follicle count, the most widely measured markers of ovarian reserve. Our goal is to provide information to rheumatologists faced with counselling patients with SLE regarding their fertility, family planning and options for assisted reproductive technologies, which now include fertility preservation through oocyte cryopreservation.
- 13 December 2022
- Published by BMJ in Lupus Science & Medicine
- Vol. 9 (1) , e000840
Open AccessInfertility in systemic lupus erythematosus: what rheumatologists need to know in a new age of assisted reproductive technology
Fertility is often a concern for women with SLE. In addition to known indirect factors that influence the ability of a woman with SLE to become pregnant, such as cytotoxic agents, other medications, advanced age and psychosocial effects of the disease, direct disease-related factors are believed to influence fertility. These include diminished ovarian reserve, menstrual irregularities (a function of disease activity) and the presence of antiphospholipid antibodies. The question of whether SLE intrinsically affects fertility, however, remains unanswered. In this review, we address known factors affecting fertility, assess current data regarding a direct impact of SLE on fertility and evaluate potential disease-related risk factors. We focus primarily on studies measuring anti-Müllerian hormone and antral follicle count, the most widely measured markers of ovarian reserve. Our goal is to provide information to rheumatologists faced with counselling patients with SLE regarding their fertility, family planning and options for assisted reproductive technologies, which now include fertility preservation through oocyte cryopreservation.
- 30 July 2022
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 29 (1) , 7-15
Outcomes of COVID-19 and Factors Associated With Its Severity Among Hospitalized Patients With and Without Systemic Rheumatic Disease During the First Wave of the Pandemic in New York City
Background/Objective: Conflicting data exist regarding whether patients with systemic rheumatic disease (SRD) experience more severe outcomes related to COVID-19. Using data from adult patients hospitalized with COVID-19 in New York City during the first wave of the pandemic, we evaluated whether patients with SRD were at an increased risk for severe outcomes. Methods: We conducted a medical records review study including patients aged ≥18 years with confirmed SARS-CoV-2 infection hospitalized at 3 NewYork-Presbyterian sites, March 3–May 15, 2020. Inverse probability of treatment weighting was applied to a multivariable logistic regression model to assess the association between SRD status and the composite of mechanical ventilation, intensive care unit admission, or death. Results: Of 3710 patients hospitalized with COVID-19 (mean [SD] age, 63.7 [17.0] years; 41% female, 29% White, and 34% Hispanic/Latinx), 92 (2.5%) had SRD. Patients with SRD had similar age and body mass index but were more likely to be female, ever smokers, and White or Black, compared with those without SRD. A higher proportion of patients with versus without SRD had hypertension and pulmonary disease, and used hydroxychloroquine, corticosteroids, and immunomodulatory/immunosuppressive medications before admission. In the weighted multivariable analysis, patients with SRD had an odds ratio of 1.24 (95% confidence interval, 1.10–1.41; p < 0.01) for the composite of mechanical ventilation, intensive care unit admission, or death, compared with patients without SRD. Conclusions: During the initial peak of the pandemic in New York City, patients with versus without SRD hospitalized with COVID-19 had a 24% increased likelihood of having severe COVID-19 after multivariable adjustment.
- 30 July 2022
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 29 (1) , 7-15
Outcomes of COVID-19 and Factors Associated With Its Severity Among Hospitalized Patients With and Without Systemic Rheumatic Disease During the First Wave of the Pandemic in New York City
Background/Objective: Conflicting data exist regarding whether patients with systemic rheumatic disease (SRD) experience more severe outcomes related to COVID-19. Using data from adult patients hospitalized with COVID-19 in New York City during the first wave of the pandemic, we evaluated whether patients with SRD were at an increased risk for severe outcomes. Methods: We conducted a medical records review study including patients aged ≥18 years with confirmed SARS-CoV-2 infection hospitalized at 3 NewYork-Presbyterian sites, March 3–May 15, 2020. Inverse probability of treatment weighting was applied to a multivariable logistic regression model to assess the association between SRD status and the composite of mechanical ventilation, intensive care unit admission, or death. Results: Of 3710 patients hospitalized with COVID-19 (mean [SD] age, 63.7 [17.0] years; 41% female, 29% White, and 34% Hispanic/Latinx), 92 (2.5%) had SRD. Patients with SRD had similar age and body mass index but were more likely to be female, ever smokers, and White or Black, compared with those without SRD. A higher proportion of patients with versus without SRD had hypertension and pulmonary disease, and used hydroxychloroquine, corticosteroids, and immunomodulatory/immunosuppressive medications before admission. In the weighted multivariable analysis, patients with SRD had an odds ratio of 1.24 (95% confidence interval, 1.10–1.41; p < 0.01) for the composite of mechanical ventilation, intensive care unit admission, or death, compared with patients without SRD. Conclusions: During the initial peak of the pandemic in New York City, patients with versus without SRD hospitalized with COVID-19 had a 24% increased likelihood of having severe COVID-19 after multivariable adjustment.
- 30 October 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (5) , 1619-1622
Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus
- 30 October 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (5) , 1619-1622
Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus
- 4 March 2021
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 28 (2) , e340-e347
The Psychosocial Impact of Undifferentiated Connective Tissue Disease on Patient Health and Well-Being
Background/Objective: Despite increased awareness of the diagnosis and treatment of undifferentiated connective tissue disease (UCTD), there is little research on related psychosocial factors. This cross-sectional study qualitatively assesses the psychosocial impact of UCTD on patient health and well-being. Methods: We identified 20 adult patients with UCTD enrolled in the UCTD and Overlap Registry at our tertiary care level hospital. A licensed clinical social worker administered a 30-minute semistructured interview by telephone. The standardized questionnaire consisted of 14 open-ended questions on UCTD. A team of physicians, research coordinators, and a social worker used grounded theory to analyze the qualitative data and identify themes. Results: Among 14/20 study participants (100% female; mean age, 53.6 ± 13.2 years [range, 27–74 years]), all had at least an associate's/bachelor's degree; 9 (64%) were White. The mean disease duration was 14.5 ± 13.5 years (range, 0.5–44 years). Nine study participants (64%) were engaged in counseling or mindfulness training. Ten specific psychosocial themes and categories emerged, including the need for professional guidance and peer and family support to increase awareness, reduce isolation, and promote self-efficacy. Conclusions: Emerging themes from semistructured interviews of women with UCTD at a major academic center suggest the need for psychosocial interventions (e.g., patient support groups, educational materials, peer counselors) to help UCTD patients manage and cope with their illness. Future studies evaluating the psychosocial impact of UCTD diagnosis on diverse cohorts are needed.
- 4 March 2021
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 28 (2) , e340-e347
The Psychosocial Impact of Undifferentiated Connective Tissue Disease on Patient Health and Well-Being
Background/Objective: Despite increased awareness of the diagnosis and treatment of undifferentiated connective tissue disease (UCTD), there is little research on related psychosocial factors. This cross-sectional study qualitatively assesses the psychosocial impact of UCTD on patient health and well-being. Methods: We identified 20 adult patients with UCTD enrolled in the UCTD and Overlap Registry at our tertiary care level hospital. A licensed clinical social worker administered a 30-minute semistructured interview by telephone. The standardized questionnaire consisted of 14 open-ended questions on UCTD. A team of physicians, research coordinators, and a social worker used grounded theory to analyze the qualitative data and identify themes. Results: Among 14/20 study participants (100% female; mean age, 53.6 ± 13.2 years [range, 27–74 years]), all had at least an associate's/bachelor's degree; 9 (64%) were White. The mean disease duration was 14.5 ± 13.5 years (range, 0.5–44 years). Nine study participants (64%) were engaged in counseling or mindfulness training. Ten specific psychosocial themes and categories emerged, including the need for professional guidance and peer and family support to increase awareness, reduce isolation, and promote self-efficacy. Conclusions: Emerging themes from semistructured interviews of women with UCTD at a major academic center suggest the need for psychosocial interventions (e.g., patient support groups, educational materials, peer counselors) to help UCTD patients manage and cope with their illness. Future studies evaluating the psychosocial impact of UCTD diagnosis on diverse cohorts are needed.